Science Explorer Back to mapMap

Most cited papers from Mersana Therapeutics (United States)

What are the most cited papers from Mersana Therapeutics (United States)?

The most cited paper from Mersana Therapeutics (United States) is "Single-vector inducible lentiviral RNAi system for oncology target validation" (Dmitri Wiederschain, W Nicolson Susan, Lin Chen et al., 2009), with 469 citations. Next come "Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial" (241) and "Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design" (137).

Showing 50 of 80 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Single-vector inducible lentiviral RNAi system for oncology target validation Dmitri Wiederschain, W Nicolson Susan, Lin Chen et al. · Cell Cycle Open access Feb 2009 469
2 Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial Ingo K. Mellinghoff, Min Lu, Patrick Yung Wen et al. · Nature Medicine Open access 23 Feb 2023 241
3 Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design Pamela A. Trail, Gene M. Dubowchik, Timothy B. Lowinger · Pharmacology & Therapeutics 27 Jul 2017 137
4 Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials Joan B. Mannick, Grace Sock Leng Teo, Bernardo Patti et al. · The Lancet Healthy Longevity Open access May 2021 122
5 A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy Alexander V. Yurkovetskiy, Mao Yin, Natalya D. Bodyak et al. · Cancer Research 26 Jun 2015 105
6 XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer Alexander V. Yurkovetskiy, Robert J. Fram · Advanced Drug Delivery Reviews Review 13 Aug 2009 99
7 Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses Naniye Malli Cetinbas, Travis E. Monnell, Jahna Soomer-James et al. · Nature Communications Open access 11 Jul 2024 87
8 Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study Benoît You, Christopher H. Purdy, Larry J. Copeland et al. · Journal of Clinical Oncology Open access 17 Oct 2022 81
9 Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect Aleksandr V. Yurkovetskiy et al. · Molecular Cancer Therapeutics 15 Mar 2021 77
10 Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid et al. · Journal of Medicinal Chemistry Open access 24 Jul 2023 56
11 The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b Natalya D. Bodyak et al. · Molecular Cancer Therapeutics 15 Mar 2021 49
12 XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells Raghida A. Bukhalid et al. · Clinical Cancer Research Open access 3 Mar 2025 44
13 Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking Xingfeng Bao et al. · Cancer Biology & Therapy Open access 2 Mar 2015 43
14 Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer Dorin Toader et al. · Molecular Cancer Therapeutics Open access 9 Jun 2023 41
15 2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs ( Part 1A – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies Surinder Kaur et al. · Bioanalysis Open access May 2022 31
16 Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies Armin Ghobadi et al. · Blood Open access 30 May 2025 30
17 Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study Charles N. Landen, Ronald J. Buckanovich, Michael W. Sill et al. · Journal of Clinical Oncology 22 May 2024 26
18 Neuropilin-1 drives tumor-specific uptake of chlorotoxin Sharon McGonigle, Utpal Majumder, Donna Kolber‐Simonds et al. · Cell Communication and Signaling Open access 17 Jun 2019 21
19 Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial Armin Ghobadi et al. · Research Square PreprintOpen access 5 Aug 2024 19
20 A generic approach for simultaneous measurements of total antibody and cleavable antibody-conjugated drug by LC/MS/MS Ling Xu, Laura E. Packer, Chao Li et al. · Analytical Biochemistry Sep 2017 19
21 An Integrated Analysis of Dostarlimab Immunogenicity Sharon M. Lu, Ronald R. Bowsher, Amanda Clancy et al. · The AAPS Journal Open access 29 Jul 2021 18
22 Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076) Debra L. Richardson, Erika Paige Hamilton, Minal A. Barve et al. · Gynecologic Oncology Aug 2022 17
23 Delivering More Payload (High DAR ADCs) Natalya D. Bodyak, Alexander V. Yurkovetskiy · Cancer drug discovery and develogment/Cancer drug discovery and development Book chapter 2018 16
24 Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment Mehmet Akce, Anthony B. El-Khoueiry, Sarina Anne Piha-Paul et al. · Cancer Chemotherapy and Pharmacology Open access 29 Jul 2021 15
25 836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate Erika Paige Hamilton, Minal A. Barve, Anthony W. Tolcher et al. · Annals of Oncology Open access Sep 2020 14
26 Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance Dana Meredith Chase, Jessica A. Perhanidis, Divya Myadam Gupta et al. · Oncology and Therapy Open access 4 Apr 2023 13
27 Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry Ling Xu, Zhiling Zhang, Shengsheng Xu et al. · Journal of Pharmaceutical and Biomedical Analysis 11 Jun 2019 13
28 Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios Susan M. Clardy et al. · Molecular Cancer Therapeutics 29 Sep 2023 10
29 Determining the Stoichiometry of a Protein–Polymer Conjugate Using Multisignal Sedimentation Velocity Analytical Ultracentrifugation Susan M. Clardy, David H. Lee, Peter Schuck · Bioconjugate Chemistry 13 Apr 2021 10
30 Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy Dana Meredith Chase, Jessica A. Perhanidis, Divya Gupta et al. · JCO Clinical Cancer Informatics Open access Jun 2023 9
31 NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort Sarah Heynemann, Hui Yu, Leonid P. Churilov et al. · Clinical Lung Cancer 16 Nov 2021 8
32 UPLIFT (ENGOT-OV67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer Debra J. Richardson et al. · Gynecologic Oncology 9 Oct 2024 7
33 Microglial roles in Alzheimer's disease: An agent‐based model to elucidate microglial spatiotemporal response to beta‐amyloid Catherine Weathered, Sophia Bardehle, Choya Yoon et al. · CPT Pharmacometrics & Systems Pharmacology Open access 11 Dec 2023 7
34 Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates Joshua D. Thomas, Aleksandr V. Yurkovetskiy, Mao Yin et al. · Bioorganic & Medicinal Chemistry Letters 3 Jul 2022 6
35 Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA) Patrick R. Conlon, Venu R. Gurijala, Michael D. Kaufman et al. · Organic Process Research & Development 15 Feb 2022 6
36 MER-1001, a novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model Alex Yurkovetskiy, Mikhail I. Papisov, Alan J. Fischman et al. · Cancer Research May 2007 6
37 Constructing the cure: engineering the next wave of antibody and cellular immune therapies Stefanie R. Bailey, Eric Bartee, Kyle G. Daniels et al. · Journal for ImmunoTherapy of Cancer Open access Aug 2025 5
38 298MO Clinical activity of emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC, in patients with TNBC who received at least one prior topoisomerase-1 inhibitor (Topo-1) ADC E.P. Hamilton, Hee-Dong Han, Nour K. Abuhadra et al. · ESMO Open Open access May 2025 5
39 184 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin, a NaPi2b-directed ADC in platinum-resistant ovarian cancer Nicole Concin, Erika Paige Hamilton, LM Randall et al. · Ovarian cancer Conference paperOpen access Oct 2021 5
40 Impact of Provider Imaging Practices on Survival Outcomes in Advanced Ovarian Cancer Angela K. Green, Deborah R. Korenstein, Carol A Aghajanian et al. · Journal of the National Comprehensive Cancer Network Open access Apr 2020 5
41 Antibody–Drug Conjugates Dorin Toader · Topics in medicinal chemistry Book chapter 2017 5
42 Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies Kevin S. McDorman, Bindu M. Bennet, Karyn A. Colman et al. · Toxicologic Pathology Feb 2024 4
43 A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation Debra L. Richardson, E. Hamilton, A. W. Tolcher et al. · Gynecologic Oncology Oct 2020 4
44 P2.09-24 MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes Hui Yu, Rebecca E. Mosher, Kimberly S. Ellison et al. · Journal of Thoracic Oncology Open access Oct 2018 4
45 PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide Niyanta N. Kumar, Vaishali S. Dixit, Howard J. Burt et al. · CPT Pharmacometrics & Systems Pharmacology Open access 31 Jul 2025 3
46 3P NaPi2b expression in high grade serous ovarian cancer: Results from combined data sets Susana N. Banerjee, Debra L. Richardson, Nicole Concin et al. · ESMO Open Open access Feb 2023 3
47 620 Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates Naniye Mallı Cetinbas, Travis E. Monnell, Winnie Lee et al. · Regular and Young Investigator Award Abstracts Conference paperOpen access Nov 2020 3
48 #168 UPLIFT (ENGOT-Ov67/GOG-3048): results from the phase 2 trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer (PROC) Nicole Concin et al. · International Journal of Gynecological Cancer Open access Mar 2024 2
49 Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates Joshua D. Thomas, Aleksandr V. Yurkovetskiy, Mao Yin et al. · Molecular Cancer Therapeutics 13 Feb 2024 2
50 33 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer Debra J. Richardson, Jill H. Tseng, Theresa Louise Werner et al. · Gynecologic Oncology Reports Open access Dec 2022 2

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.